Ocugen, Inc. 8K

Ocugen issued a Q2 2026 business update and financial results, detailing late‑stage gene therapy pipeline progress and timelines along with a larger net loss, improved cash, reduced debt, and a new convertible note financing structure.

Ocugen, Inc. provided a second quarter 2026 business and financial update, highlighting execution across three ophthalmic gene therapy programs—OCU410 for geographic atrophy, OCU410ST for Stargardt disease, and OCU400 for retinitis pigmentosa—with completed or ongoing pivotal-stage trials, defined timelines for topline data and BLA submissions between 2027 and 2028, regulatory designations and alignment with FDA and EMA, and ex‑U.S. partnering activity, while reporting an unaudited Q2 2026 net loss of $24.9 million, increased R&D and G&A expenses, a strengthened cash position of $100.4 million, reduced traditional debt, and a new $116.1 million convertible note outstanding alongside higher shares outstanding versus year‑end 2025.

Filing Facts

CIK

1372299

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-091691

Alert Tier

6